<DOC>
	<DOCNO>NCT02344628</DOCNO>
	<brief_summary>The study single blind , randomize , control open label non-inferiority phase III , trial two parallel group , conduct Ghana Papua New Guinea ( PNG ) . The ultimate goal establish 20mg/kg dose azithromycin effective 30mg/kg dose treatment yaw . Approximately 600 clinically serologically diagnosed yaw patient include study . Patients randomize receive treatment two antibiotic regimen follow : ( ) Regimen I ( AZT20 ) : Single oral dose 20 mg/kg azithromycin ( ii ) Regimen II ( AZT30 ) : Single oral dose 30 mg/kg azithromycin . The follow-up period patient 6 month . Assessments , antibiotic treatment include full medical history , clinical assessment lesion , laboratory investigation . The primary efficacy parameter heal lesion 4 week four-fold decline RPR titre 6 month start treatment .</brief_summary>
	<brief_title>Comparison Two Different Doses Azithromycin Treatment Yaws</brief_title>
	<detailed_description />
	<criteria>Aged 6 16 year Clinical lesion consistent primary secondary yaw Primary ulcer papilloma DuallyPositive Chembio DPP Syphilis Screen &amp; Confirm Informed Consent Assent ( child 1216 year ) 1 . Known allergy azithromycin macrolides . 2 . Treatment longacting penicillin alternative antibiotic activity T. pallidum within last 3 month ( ceftriaxone , azithromycin doxycycline , amoxicillin ) . 3 . Patients current treatment drug likely interact study medication . 4 . Patients unable take oral medication gastrointestinal disease likely interfere drug absorption . 5 . Patients may able comply requirement study protocol include follow visit . 6 . Patients willing give inform consent ( patient and/or parent/legal representative ) , withdraw consent .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>